Trial Profile

AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Telisotuzumab adizutecan (Primary) ; Tipiracil/trifluridine (Primary)
Indications Colorectal cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms AndroMETa-CRC
Sponsors AbbVie

17 Jul 2025 Planned End Date changed from 1 Apr 2029 to 1 Oct 2028.
17 Jul 2025 Planned primary completion date changed from 1 Apr 2029 to 1 Oct 2028.
26 Nov 2024 Planned End Date changed from 6 Apr 2029 to 1 Apr 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com